Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial. | LitMetric
Department of Radiation Oncology, University of Nebraska Medical Center, 987521 Nebraska Medical Center, Ground Floor, Clarkson Tower, Omaha, NE, 68198, USA.
Published: April 2017
AI Article Synopsis
Article Abstract
Background: This is the first known study examining renal function following stereotactic body radiotherapy (SBRT) for pancreatic head adenocarcinoma.
Methods: Thirty-eight borderline-resectable/unresectable patients, part of an ongoing prospective trial, underwent 3 cycles of gemcitabine/5-fluorouracil followed by SBRT (5 daily fractions of 5/6/7/8 Gy) and concurrent nelfinavir. Thereafter, in resectable cases, surgery was performed within 4-8 weeks. The last available pre-SBRT creatinine was recorded, along with the highest post-SBRT value. Glomerular filtration rate (GFR) was calculated by the commonly-utilized Modification of Diet in Renal Disease formula. GFR decline was defined as the post-SBRT nadir GFR minus the pre-SBRT GFR. Correlations with the V5-V30, and mean/maximum kidney doses was performed. Statistics included Pearson correlation, Mann-Whitney, and Fisher's exact tests.
Results: The median total kidney volume was 355 cm. Median dosimetric values were as follows: V5 (209 cm), V10 (103 cm), V15 (9 cm), V20 (0 cm), V25 (0 cm); and mean (6.7 Gy) & maximum kidney dose (18.3 Gy). Median GFR change was -23 (range, -105 to 25) mL/min/1.73 cm. Of all dosimetric parameters, only V5 was significantly associated with changes in GFR (Pearson r = -0.40, p = 0.012). In patients with V5 < 210 cm, median GFR change was -11.8 mL/min/1.73 cm, as compared with -37.1 mL/min/1.73 cm change in those with V5 ≥ 210 cm (p = 0.02). A GFR change < -23 mL/min/1.73 cm was observed in 6/20 (30%) patients with V5 < 210 cm, versus 15/18 (83%) of those with V5 ≥ 210 cm. Patients with V5 ≥ 210 cm were over ten times as likely to have GFR change < -23 mL/min/1.73 cm (p = 0.003). Using linear regression, GFR change ≈ -0.1748 × V5(cm) + 8.63.
Conclusions: In the first known analysis of renal function after pancreatic SBRT, evaluating patients on a prospective study, V5 ≥ 210 cm was associated with a post-SBRT GFR decline of >23 mL/min/1.73 cm. If V5 is kept <210 cm, median GFR decline was only 11.8 mL/min/1.73 cm. Further validation is needed to ascertain definite dose-volume parameters and examine late renal decline.
